Last updated: August 1, 2026
Pharmachemie B.V. is a Netherlands-based pharmaceutical operating entity within Teva Pharmaceutical Industries Ltd., rather than an independent branded-drug company. Its strategic value is tied to Teva’s European generic medicines platform, Dutch manufacturing and regulatory infrastructure, and access to a broad portfolio of off-patent and specialty medicines. Pharmachemie’s competitive position is strongest in regulated European markets where supply reliability, dossier ownership, GMP compliance and tender execution determine market access.
Public disclosures do not identify Pharmachemie as a standalone owner of a distinct global patent estate. Product patents, marketing authorizations and commercial rights are generally held across Teva affiliates or licensed from third parties. As a result, competitive analysis should evaluate Pharmachemie as part of Teva’s integrated generics and specialty-pharmaceutical network.
What is Pharmachemie B.V. and how does it fit within Teva?
Pharmachemie B.V. is a Dutch pharmaceutical company associated with Teva’s European operations. Its activities include pharmaceutical manufacturing, regulatory support and commercialization of generic medicines. The company is based in the Netherlands and has historically been associated with Teva’s Haarlem operations.
| Category |
Assessment |
| Legal entity |
Pharmachemie B.V. |
| Country |
Netherlands |
| Parent group |
Teva Pharmaceutical Industries Ltd. |
| Primary role |
European pharmaceutical manufacturing and operating entity |
| Main commercial exposure |
Generic medicines, specialty products and hospital or pharmacy channels |
| Core regulatory environment |
European Union and Dutch medicines regulation |
| Standalone public listing |
No |
| Primary strategic asset |
Integration into Teva’s global generic portfolio and supply chain |
| Main competitive risks |
Price erosion, tender concentration, manufacturing costs and parent-level restructuring |
Teva reports its business primarily through global segments rather than individual legal entities. Its key pharmaceutical categories include generic medicines, innovative medicines and active pharmaceutical ingredients. Pharmachemie therefore contributes to a larger platform rather than reporting independent revenue, operating margins or product-level profitability.
What products and therapeutic areas are associated with Pharmachemie?
Pharmachemie’s product exposure is principally linked to Teva’s generic and specialty portfolios. The relevant dosage forms can include tablets, capsules, oral liquids, injectables and other finished pharmaceutical forms, depending on the product and manufacturing authorization.
Product-level attribution changes over time because Teva regularly transfers manufacturing activities, rationalizes products and adjusts market supply arrangements. The most relevant therapeutic categories for a Teva-affiliated European generic operation include:
- Central nervous system medicines
- Respiratory medicines
- Cardiovascular products
- Oncology and supportive-care products
- Anti-infective medicines
- Gastrointestinal medicines
- Women’s health products
- Hospital and injectable products
- Select specialty and complex generic medicines
Teva’s global generic portfolio includes products marketed under local national brands, international generic names and Teva trademarks. Pharmachemie should therefore not be treated as a consumer-facing brand portfolio equivalent to a single-drug manufacturer.
How does Pharmachemie’s product model compare with branded pharmaceutical companies?
Pharmachemie competes primarily through product breadth, regulatory approvals, manufacturing continuity and price. Branded pharmaceutical companies compete through patent exclusivity, clinical differentiation and commercial promotion.
| Factor |
Pharmachemie and Teva generics |
Branded pharmaceutical company |
| Revenue model |
Volume and price-driven |
Exclusivity and differentiated pricing |
| Main legal asset |
Marketing authorization, dossier, manufacturing capability and selected patents |
Composition, formulation, method-of-use and biologic patents |
| Market entry |
After originator exclusivity or through authorized arrangements |
Before generic competition |
| Pricing pressure |
High |
Lower during exclusivity |
| Commercial channel |
Retail pharmacy, hospital and government tenders |
Specialist, hospital and direct commercial channels |
| Key risk |
Multiple competitors entering simultaneously |
Patent litigation and clinical failure |
How strong is the Pharmachemie patent estate?
Pharmachemie does not present a clearly separable patent estate comparable to an originator pharmaceutical company. The relevant intellectual-property position is distributed across Teva entities, product-specific patent owners, license agreements and regulatory exclusivity rights.
The main sources of competitive protection are:
- Teva-owned patents covering selected active ingredients, formulations, delivery systems or manufacturing processes.
- Licensed patents and commercial agreements with third-party originators or technology providers.
- Regulatory data and market exclusivity.
- Product dossiers and bioequivalence data.
- Manufacturing know-how and validated GMP processes.
- Market-specific approvals and supply arrangements.
For standard small-molecule generics, patent protection usually limits the timing of entry into a market rather than creating long-term monopoly economics. Pharmachemie’s strongest intellectual-property positions are more likely to arise in complex generics, injectable products, inhalation systems, modified-release formulations and products requiring difficult manufacturing or bioequivalence studies.
What patents protect Pharmachemie products?
Patent protection depends on the specific active ingredient and market. The legal entity named on a patent may be Teva Pharmaceutical Industries Ltd., an affiliated Teva company or a third-party licensor rather than Pharmachemie B.V.
Relevant patent categories include:
| Patent category |
Strategic relevance |
| Active-ingredient patent |
Controls basic market entry before expiry |
| Polymorph or salt patent |
Can complicate generic development |
| Formulation patent |
Protects release profile, stability or dosage form |
| Device patent |
Relevant to inhalers, injectors and delivery systems |
| Method-of-use patent |
May restrict a labeled indication |
| Manufacturing-process patent |
Can create technical barriers but may be difficult to enforce |
| Packaging or combination patent |
Usually narrower commercial protection |
| Patent cooperation or license rights |
Can determine whether Teva may commercialize a product |
A product-by-product patent review requires matching each national marketing authorization to patent-family data, regulatory exclusivity and Teva’s ownership or license position. Pharmachemie’s corporate name alone does not identify the applicable patent rights.
What is the Orange Book status of Pharmachemie products?
The FDA Orange Book is generally not a primary source for Pharmachemie’s European commercial position. The Orange Book lists approved drug products and patents or exclusivity associated with U.S. applications. A Pharmachemie manufacturing site may appear in U.S. regulatory records, but the relevant U.S. applicant, NDA holder or ANDA sponsor may be another Teva entity.
For U.S. products, the appropriate review sequence is:
- Identify the NDA or ANDA holder.
- Confirm whether Teva or an affiliate owns or licenses the product.
- Review listed patents in the Orange Book.
- Assess Paragraph IV certification activity.
- Check whether litigation was filed within the statutory 45-day period.
- Review settlement terms, pediatric exclusivity and any regulatory stay.
- Separate manufacturing-site information from legal ownership.
The Orange Book should not be used to infer that Pharmachemie owns a particular U.S. patent or controls U.S. launch timing.
How do Paragraph IV challenges affect Teva and Pharmachemie?
Teva is one of the largest global generic companies and has historically participated in Paragraph IV litigation involving branded medicines. Such cases normally arise at the Teva applicant or parent-affiliate level, not under Pharmachemie’s name.
Paragraph IV exposure can create two outcomes:
- An early generic launch opportunity if the challenged patent is invalid, unenforceable or not infringed.
- Litigation expense and delayed launch if the originator obtains a stay, injunction or favorable judgment.
The commercial value of a successful challenge depends on the number of competing ANDAs, the length of the remaining patent term, the presence of authorized generics and the product’s pre-entry sales.
When does Pharmachemie lose exclusivity?
Pharmachemie does not have one company-wide exclusivity date. Exclusivity is product-specific and jurisdiction-specific.
For small-molecule medicines, relevant dates can include:
- Compound-patent expiration
- Formulation-patent expiration
- Method-of-use patent expiration
- Supplementary protection certificate expiration in Europe
- Regulatory data exclusivity expiration
- Market exclusivity expiration
- Pediatric extension
- Settlement-based launch date
- Manufacturing or supply agreement termination
In the European Union, the standard regulatory framework is often described through the eight-year data-exclusivity period, followed by a two-year market-exclusivity period, with a possible one-year extension for a significant new indication under applicable rules. Patent and supplementary protection certificate terms can extend beyond regulatory exclusivity.
In the United States, generic launch timing may depend on the Hatch-Waxman framework, Orange Book-listed patents, Paragraph IV litigation, first-filer status and pediatric exclusivity.
What patent expiration dates matter?
The relevant expiration date is the latest enforceable right that covers the proposed product and intended use. A compound patent may expire before a formulation or method-of-use patent. A process patent may have limited practical importance if a competitor can manufacture the product through a non-infringing process.
A competitive patent review should record:
| Date field |
Why it matters |
| Earliest composition expiry |
Indicates first possible basic generic entry |
| Latest formulation expiry |
May delay a specific dosage form |
| Method-of-use expiry |
Can restrict indication-specific labeling |
| SPC expiry |
Extends European protection for eligible products |
| Regulatory exclusivity expiry |
Determines dossier-based entry rights |
| Settlement launch date |
May establish the actual commercial entry date |
| Pediatric extension |
Can move the effective barrier by six months in qualifying cases |
Which companies compete with Pharmachemie?
Pharmachemie competes indirectly through Teva against large multinational generic manufacturers and regional European suppliers.
Principal multinational competitors
- Sandoz
- Viatris
- STADA Arzneimittel
- Zentiva
- Sun Pharmaceutical Industries
- Fresenius Kabi
- Hikma Pharmaceuticals
- Accord Healthcare
- Lupin
- Dr. Reddy’s Laboratories
European and regional competitors
- Krka
- Polpharma
- Aspen Pharmacare
- Medochemie
- Aurobindo-affiliated companies
- Generic manufacturers supplying national tenders and pharmacy chains
Competitive intensity differs by product. A high-volume oral solid may have numerous approved suppliers, while an injectable, inhaled product or complex formulation may have fewer qualified competitors.
| Competitive factor |
Pharmachemie/Teva position |
Main challenger group |
| European generic breadth |
Strong |
Sandoz, Viatris, STADA |
| Global regulatory reach |
Strong |
Sandoz, Viatris, Sun |
| Dutch manufacturing presence |
Relevant |
Local and European manufacturers |
| Complex generics |
Selective strength |
Sandoz, Viatris, Fresenius Kabi, Accord |
| Hospital injectables |
Product-dependent |
Fresenius Kabi, Hikma, Accord |
| Low-cost oral solids |
Competitive but pressured |
Krka, Zentiva, Asian suppliers |
| Specialty medicines |
Stronger than many regional generics |
Branded and specialty-generic firms |
What are Pharmachemie’s main commercial strengths?
Pharmachemie’s strengths derive from its connection to Teva rather than from independent corporate scale.
European regulatory infrastructure
Teva maintains extensive experience with European marketing authorization procedures, decentralized procedures, mutual-recognition procedures and national filings. This supports rapid deployment of generic dossiers across multiple markets.
Manufacturing and quality systems
A regulated European manufacturing base can support supply to markets that require documented GMP compliance, local release arrangements or robust quality oversight. Manufacturing proximity can reduce certain logistics and geopolitical risks, although it does not eliminate exposure to imported active pharmaceutical ingredients.
Portfolio breadth
Teva’s portfolio allows cross-selling across pharmacy, hospital and specialty channels. A broad product base can support tenders and wholesaler relationships that would be difficult for a single-product manufacturer to establish.
Complex-product capability
Teva has invested in respiratory, injectable, biosimilar and other complex products. These categories have higher development and regulatory barriers than conventional immediate-release tablets.
Global procurement
Teva’s group scale provides purchasing and supply-chain leverage. It can also spread development, pharmacovigilance and regulatory costs across multiple national markets.
What are Pharmachemie’s main weaknesses?
The company’s weaknesses are closely connected to the economics of mature generic markets.
High price erosion
Generic prices often decline rapidly after multiple suppliers receive approval. National reimbursement systems and public tenders can intensify this pressure.
Parent-level restructuring
Teva has undertaken restructuring, portfolio rationalization and cost-reduction programs over several years. These measures can affect product availability, manufacturing allocations and internal investment priorities. Teva reported substantial debt and restructuring activity in its public filings, making capital discipline a continuing strategic issue (Teva Pharmaceutical Industries Ltd., 2024).
Dutch operating costs
A Netherlands-based operation faces higher labor, compliance and facility costs than manufacturing platforms in lower-cost jurisdictions. This disadvantage can be offset by quality, proximity and supply reliability but remains material in commodity products.
Product concentration at the market level
Even a large portfolio can have concentrated exposure in individual countries or hospital tenders. Loss of one contract can materially affect a product’s local volume.
Limited standalone visibility
Because Pharmachemie is reported within Teva, investors and counterparties generally cannot isolate its revenue, margins, patent value or product profitability from public filings.
What manufacturing and intellectual-property barriers affect Pharmachemie?
Manufacturing barriers can be more important than patents in complex generics. Relevant barriers include:
- Difficult bioequivalence requirements
- Specialized analytical testing
- Inhalation-device performance
- Sterile manufacturing validation
- Extractables and leachables testing
- Stability and impurity control
- Low-solubility active ingredients
- Complex release mechanisms
- Device-drug combination approvals
- Limited availability of qualified active-ingredient suppliers
In Europe, manufacturing sites must comply with applicable EU GMP requirements and remain subject to inspection and regulatory oversight. The European Medicines Agency and national authorities publish regulatory information for authorized products and manufacturing sites through relevant databases, including EudraGMDP.
For biosimilars, the competitive barrier is higher. Biosimilar developers must generate analytical, clinical and immunogenicity evidence under the applicable regulatory pathway. Pharmachemie may benefit from Teva’s broader biosimilar capabilities, but biosimilar competition should be analyzed at the Teva product and affiliate level rather than assumed from the Pharmachemie legal entity.
What is the FDA regulatory status of Pharmachemie?
Pharmachemie-related facilities or products may support U.S. applications, but FDA status is product-specific. The company’s presence in FDA records does not itself establish that Pharmachemie holds a U.S. marketing authorization.
A U.S. diligence review should distinguish among:
- Drug establishment registration
- FDA inspection status
- Manufacturing-site listing
- ANDA approval
- NDA ownership
- Contract manufacturing
- Teva affiliate sponsorship
- Warning letters or import alerts
- Product-specific recalls
FDA manufacturing registration is not equivalent to FDA approval of a drug product. The relevant commercial rights rest with the application holder and the approved labeling, while manufacturing activities may be performed by an affiliate or contractor.
What litigation and settlement agreements affect Pharmachemie?
Public litigation involving Teva generally concerns specific products, patents and legal entities. Pharmachemie may be involved as a manufacturer, affiliate or operational entity without being the named party in the core patent dispute.
The most relevant litigation categories are:
- ANDA patent litigation in the United States.
- European national patent litigation.
- Product liability and commercial disputes.
- Antitrust litigation involving generic pricing or distribution.
- Manufacturing-quality and regulatory enforcement matters.
- Contract disputes with licensors, suppliers or distributors.
Settlement agreements may establish a future generic launch date, supply rights, royalties, restrictions on indication labeling or authorized-generic terms. A settlement affecting a Teva affiliate does not automatically apply to all Pharmachemie products or markets.
How does Pharmachemie compare with Sandoz and Viatris?
| Metric |
Pharmachemie/Teva |
Sandoz |
Viatris |
| Corporate scale |
Global Teva platform |
Global standalone generics company |
Global branded-generics company |
| Dutch operating relevance |
Material through Pharmachemie |
Market-specific |
Market-specific |
| Generic portfolio |
Broad |
Broad |
Broad |
| Complex generics |
Meaningful |
Strong |
Meaningful |
| Biosimilars |
Teva has relevant capability |
Major strategic focus |
Significant portfolio |
| Capital constraints |
Parent deleveraging remains relevant |
Standalone capital allocation |
Portfolio and debt management |
| Core advantage |
Integrated global infrastructure |
Focused generics identity |
Broad commercial footprint |
| Key risk |
Product rationalization and price pressure |
Generic price erosion |
Integration and portfolio complexity |
Pharmachemie’s differentiation is operational. It is not a separate strategic challenger to Sandoz or Viatris; it is part of Teva’s response to them.
What generic launch risks exist for Pharmachemie?
Generic launch risk depends on both legal and operational factors.
| Risk |
Commercial effect |
| Patent litigation |
Delays launch or increases legal cost |
| Multiple ANDA or EU applicants |
Reduces post-launch price and share |
| Regulatory deficiency |
Delays approval or requires additional studies |
| Manufacturing deviation |
Creates shortages, recalls or approval risk |
| Tender loss |
Removes volume despite regulatory approval |
| Active-ingredient shortage |
Interrupts supply |
| Authorized generic launch |
Limits price and share upside |
| Labeling restrictions |
Reduces addressable indication |
| Settlement limitations |
Restricts launch timing |
| Reimbursement exclusion |
Prevents commercial uptake |
The highest-value launches are typically those with limited competition, meaningful originator sales, manageable patent exposure and technically defensible manufacturing requirements.
What licensing deals and partnerships matter?
Teva’s product portfolio includes internally developed products, acquisitions, co-development arrangements, licensing agreements and manufacturing relationships. Pharmachemie’s commercial access to a product may therefore depend on rights held by Teva or another affiliate.
A licensing review should test:
- Territory covered
- Exclusive or nonexclusive rights
- Patent and regulatory ownership
- Royalty obligations
- Minimum purchase requirements
- Manufacturing responsibilities
- Termination rights
- Change-of-control provisions
- Rights after patent expiry
- Pharmacovigilance and recall obligations
No single public licensing agreement defines Pharmachemie’s market position. The decisive agreements are product-specific and may be disclosed through Teva filings, regulatory records, transaction announcements or litigation documents.
What is the revenue exposure of Pharmachemie?
Pharmachemie does not publish a separate revenue segment in Teva’s principal financial reporting. Revenue exposure must therefore be assessed through Teva’s European generic sales, product-level disclosures and the importance of Dutch manufacturing operations.
The principal revenue drivers are:
- Product volume
- Net price after rebates and clawbacks
- Tender wins
- Pharmacy substitution rules
- Hospital procurement
- New generic launches
- Loss of exclusivity
- Supply continuity
- Foreign-exchange movements
- Portfolio withdrawals
A high-volume product with several approved suppliers can generate less strategic value than a lower-volume complex generic with limited competition. Manufacturing contribution also depends on transfer pricing and whether the Dutch entity records manufacturing revenue, service revenue or intercompany income.
What is Pharmachemie’s strategic outlook?
Pharmachemie’s strategic value is likely to remain tied to four priorities:
- Maintaining compliant and reliable European manufacturing.
- Supporting Teva’s differentiated and complex-generic pipeline.
- Protecting supply continuity in regulated markets.
- Reducing exposure to low-margin products with excessive competition.
The strongest strategic path is selective participation in products where regulatory complexity, manufacturing know-how or supply reliability limits competitor entry. Commodity products with many approved manufacturers face weaker economics, particularly where national tenders reward the lowest sustainable price.
For investors, licensors and competitors, Pharmachemie should be evaluated as a node in Teva’s European operating network. The key diligence questions concern product ownership, site authorization, affiliate relationships, patent rights, manufacturing allocation and Teva’s plans for each product category.
Key Takeaways
- Pharmachemie B.V. is a Dutch Teva-affiliated pharmaceutical operating and manufacturing entity.
- It is not publicly reported as an independent global pharmaceutical segment.
- Its competitive position depends on Teva’s portfolio, regulatory platform, manufacturing capability and supply-chain scale.
- Pharmachemie does not have a clearly separable standalone patent estate.
- U.S. Orange Book and Paragraph IV analysis must be conducted at the NDA, ANDA and Teva-affiliate level.
- The main competitors are Sandoz, Viatris, STADA, Zentiva, Sun Pharma, Fresenius Kabi, Accord and Hikma.
- Complex generics, injectables, inhaled products and biosimilars offer stronger barriers than commodity tablets.
- Price erosion, tender concentration, Dutch operating costs and Teva’s restructuring remain central commercial risks.
- Patent expiration, regulatory exclusivity, settlement terms and manufacturing readiness must be reviewed product by product.
- Pharmachemie’s strategic importance is operational and network-based rather than tied to a separately disclosed brand or patent franchise.
FAQs About Pharmachemie B.V.
Is Pharmachemie B.V. owned by Teva?
Yes. Pharmachemie B.V. is associated with Teva’s Netherlands and European operations and forms part of Teva’s broader pharmaceutical business.
Does Pharmachemie manufacture generic medicines?
Yes. Its activities are associated with pharmaceutical manufacturing and Teva’s generic medicines platform, subject to product-specific manufacturing authorizations and allocations.
Does Pharmachemie own patents?
Patent ownership is product-specific. Relevant rights may be held by Teva Pharmaceutical Industries Ltd., a Teva affiliate or a third-party licensor rather than Pharmachemie B.V.
Is Pharmachemie a competitor to Sandoz?
Pharmachemie competes against Sandoz through Teva’s European generic and specialty-pharmaceutical operations. The competitive comparison is more meaningful at the Teva group or product level.
Can Pharmachemie launch a generic before patent expiry?
Potentially, depending on the jurisdiction, patent scope, validity, non-infringement position, regulatory approval, litigation outcome and any settlement agreement. A manufacturing site does not independently determine launch timing.
References
-
European Medicines Agency. (n.d.). EudraGMDP database. https://eudragmdp.ema.europa.eu/
-
European Medicines Agency. (n.d.). Generic and hybrid medicines. https://www.ema.europa.eu/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process for generic drugs. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
-
Teva Pharmaceutical Industries Ltd. (2024). Annual report on Form 20-F for the year ended December 31, 2023. https://www.teva.com/investors/financial-information/
-
Teva Pharmaceutical Industries Ltd. (2025). Annual report on Form 20-F for the year ended December 31, 2024. https://www.teva.com/investors/financial-information/
-
European Commission. (n.d.). Supplementary protection certificates for pharmaceutical and plant protection products. https://single-market-economy.ec.europa.eu/industry/strategy/intellectual-property/patent-protection-eu/supplementary-protection-certificates_en
